30% of participants showed a viable response to ARI’s cellular regeneration techniques. ......30%
Yet, they proceeded with the more expensive phase II trials. There's obviously something that we aren't seeing. I just can't imagine their primary investors allowing them to spend more money on a treatment that isn't viable.
Comment